Nebivolol Ophthalmic Suspension 1 Percent
BTQ-1901-1902-201
Phase 2 small_molecule completed
Quick answer
Nebivolol Ophthalmic Suspension 1 Percent for Open-Angle Glaucoma is a Phase 2 program (small_molecule) at Summit Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Summit Therapeutics
- Indication
- Open-Angle Glaucoma
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed